New hope for kidney transplant patients: a better way to prevent a dangerous virus?

This study tests whether a newer drug, letermovir, works better than the standard valganciclovir to prevent CMV (a common virus) in African American kidney transplant recipients. About 30 high-risk patients will take letermovir for 6 months after transplant, and their results will be compared to a similar group who took valganciclovir. The goal is to see which drug better prevents CMV infection and has fewer side effects like low white blood cell counts.